EGCG identified as an autophagy inducer for rosacea therapy

Area of Science:

• Dermatology
• Molecular Biology
• Pharmacology

Background:

• Rosacea is a common facial inflammatory condition.
• Hyperactivation of mTORC1 signaling in the epidermis is a key feature.
• Limited effective treatment options exist due to unclear pathogenesis.

Purpose of the Study:

• Investigate the relationship between epidermal autophagy and mTOR pathways in rosacea.
• Identify potential therapeutic agents for rosacea.
• Validate the therapeutic efficacy of identified agents.

Main Methods:

• Weighted gene co-expression network analysis (WGCNA) to identify gene modules.
• Immunofluorescence and qPCR for validation.
• In vivo and in vitro experiments to assess therapeutic effects.
• Drug-target prediction and molecular docking.

Main Results:

• Autophagy is downregulated in rosacea epidermis and regulated by mTOR.
• Epigallocatechin-3-gallate (EGCG) was identified as a potential therapeutic agent.
• EGCG demonstrated therapeutic effects in vivo and in vitro by inducing autophagy.
• Potential targets for EGCG include AKT1/MAPK1/MMP9.

Conclusions:

• Autophagy plays a critical role in rosacea pathogenesis.
• EGCG effectively attenuates rosacea-like inflammation by inducing autophagy in keratinocytes.
• EGCG represents a promising therapeutic strategy for rosacea treatment.